In some embodiments, the formulations described herein have a pH and/or practical osmolarity as described herein, and have a concentration of active pharmaceutical ingredient from about 0.0001% to about 60%, from about 0.001% to about 40%, from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.01% to about 7.5%, from about 0.01% to about 6%, from about 0.01 to about 5%, from about 0.1 to about 10%, or from about 0.1 to about 6% of the active ingredient by weight of the formulation
Dos Santos et al., in his report RFA for NDBE and LGD in combo with antireflux procedure, describes a new clinical pathway for Barretts esophagus, offering patients a combination of 2 treatment modalities: RFA of abnormal esophageal mucosa and an antireux procedure to minimize continuing acid injury to the esophagus
Kada osoba ktra go stosuje jest de facto uczestnikiem niekontrolowanego eksperymentu na sobie
2830
Continued preclinical investigation will be necessary to clarify its mechanisms and determine what, if anything, this research model can reveal about broader tissue repair biology.
